Ironwood Pharmaceuticals Announces Conference Call to Discuss Positive Linaclotide Phase 3 IBS-C Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced it will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, November 2, 2010 to discuss the positive top-line results of its second Phase 3 clinical trial assessing the efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C). Individuals interested in participating in the call should dial (888) 213-3752 (U.S. and Canada) or (913) 312-0840 (international) using conference ID number 2151484. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. The call will be available for replay via telephone starting November 2, 2010 at 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on November 19, 2010. To listen to the replay, dial (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international) using conference ID number 2151484. An archived version of the event will be available on Ironwood’s website for 14 days beginning approximately one hour after the call.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood’s GC‐C agonist, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS‐C) and chronic constipation. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass.



CONTACT:

Ironwood Pharmaceuticals, Inc.
Susan Brady, 617-621-8304
Corporate Communications
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.